← Leaderboards
Thomas Jack Schnitzer
Northwestern University At Chicago
$1,067,608
Attributed
$2,414,650
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $956.6K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$2,414,650 · 2
By mechanism
R01$2,020,563 · 1
R34$394,087 · 1
Top collaborators
- Apkar Vania Apkarian3 shared
- James William Griffith3 shared
Most similar at Northwestern University At Chicago
Same institution · by research overlap
- James William Griffith$7,291,641
Others in their field
Other Rising Stars on “Serum”
- Sabrina Paganoni · Massachusetts General Hospital$25,017,559
- Suma Babu · Massachusetts General Hospital$25,017,559
- Jinsy Andrews · Columbia University Health Sciences$11,474,975
- Eric Anderson · Columbia University Health Sciences$11,474,975
- Benjamin M Greenberg · Ut Southwestern Medical Center$11,474,975
- Mariet Allen · Mayo Clinic Jacksonville$9,602,417
Research focus
SerumFunding OpportunitiesPersonsClinical TrialsRandomizedInhibitorImageParticipantResponseSiteBiological MarkersBlindedPlacebosKneeDesignClinical Outcome MeasuresAttentionClinical PhenotypeAnatomyClinical BiomarkersClinical DataBrain ImagingBrain CircuitryBrain Based
Grant awards (5)
Brain-based and clinical phenotyping of pain pharmacotherapy in knee OA$619,637
R01 · FY2025 · AR · contact PI
Denosumab and sequential zoledronic acid to prevent bone loss and maintain bone mass after spinal cord injury$114,733
R34 · FY2025 · AR · contact PI
Brain-based and clinical phenotyping of pain pharmacotherapy in knee OA$677,252
R01 · FY2024 · AR · contact PI
Denosumab and sequential zoledronic acid to prevent bone loss and maintain bone mass after spinal cord injury$279,354
R34 · FY2024 · AR · contact PI
Brain-based and clinical phenotyping of pain pharmacotherapy in knee OA$723,674
R01 · FY2023 · AR · contact PI